Metronomic chemotherapy refers to the chronic, equally spaced, delivery of low doses of chemotherapeutic drugs, without extended interruptions. Previously, we developed two combined metronomic schemes for the treatment of murine mammary tumors. The aim of this study was to compare their effects on tumor and metastasis growth, survival and toxicity. Metronomic chemotherapy with Cyclophosphamide + Celecoxib showed higher antimetastatic power than Cyclophosphamide + Doxorubicin, while being similar in other aspects. That difference, plus the advantage that represents its oral administration, points at the election of Cyclophosphamide + Celecoxib combination for the metronomic treatment of mammary tumors.
INTRODUCTION
Metastatic breast cancer, as most of advanced tumors, remains incurable, and its treatment is limited to palliative management, with the objective to prolong progression free survival, overall survival and provide an acceptable quality of life. The problem of metastatic breast cancer management persists, in spite of having a good response, at least in local stages and despite the inclusion of new targeted agents which usually have a modest impact in therapeutic efficacy (1, 2) .
The concept of metronomic chemotherapy (MCT) is well known in the oncology research area. Briefly, it refers to the chronic administration of low doses of chemotherapeutic drugs, at frequent and regular intervals, without extended rest periods, allowing a continuous and chronic treatment for different kinds of tumors, without side effects or severe toxicity (3) .
Prolonged rest periods, needed after a standard chemotherapy for the recovery of patients from common toxicities, represent an opportunity for specific and resistant cancer cells to re-grow. Those facts underline the importance of avoiding or reducing rest periods. . Several mechanisms of action like inhibition of angiogenesis, restoration of anti-tumor immune response and induction of tumor dormancy, has been proposed to explain MCT therapeutic effect (4, 5).
Cox-2 plays an important role in carcinogenesis and tumor growth and progression (6) (7) (8) (9) .
This enzyme is frequently expressed in invasive and in situ breast cancers (10, 11) . The use of Cox-2 inhibitors in cancer therapy has proved to be effective, inhibiting cell proliferation and angiogenesis.
In the same way, Cyclophosphamide, an alkylating agent that has been used for decades and it is presently used in standard chemotherapy, is one of the first and most studied drugs in metronomic or low dose administration settings. Its antiangiogenic and immunomodulating effects were probed in different experimental tumor-models and also in the clinic (3).
Doxorubicin is an anthracycline widely used in cancer chemotherapy, commonly utilized for treating several types of cancers. Different authors found that the metronomic administration of this drug, alone or in combination with Cy, brings about an antitumor an antimetastatic effect (5, 12, 13) .
Considering the high incidence of mammary tumors in humans, we had studied the therapeutic efficacy and the mechanism/s of action of MCT with cyclophosphamide (Cy) as a single drug and combined with Celecoxib (Cel) (14) , or with doxorubicin (Dox) (5), in two mouse mammary adenocarcinomas (MA) tumor-models.
The aim of the present work was to compare the results previously obtained on efficacy and toxicity in animals bearing two different MA, treated with two different MCT regimens:
Cy+Cel or Cy+Dox.
MATERIALS AND METHODS

Animals.
Inbred BALB/c and CBi female mice were obtained from our breeding facilities. Animals were fed with commercial chow and water ad libitum and maintained in a 12-h light/dark cycle. All the experiments were developed during the first half of the light cycle. Tumorbearing mice were euthanized by CO2 exposure. The animals were treated in accordance to the Canadian Council on Animal Care guidelines (15).
Drugs.
Cyclophosphamide (Laboratorio Filaxis, SA, Argentina) was dissolved in sterile distilled water at a concentration of 20 mg/ml and diluted in the drinking water to reach 0.12 mg/ml.
Drinking water was replaced every other day and the mice's daily Cy intake/kg body weight (BW) was calculated.
Doxorubicin (Laboratorio Filaxis, SA, Argentina) was dissolved in sterile saline immediately before its intraperitoneal injection.
Celecoxib (Pfizer Corp, Chicago, USA) was dissolved in dimethylsulfoxide at a concentration of 200 mg/ml. Immediately before its administration by gavage, it was further diluted with phosphate buffer saline to a concentration of 2 mg/ml (8) .
Tumors
The mouse mammary tumors M-234p and M-406, established in our laboratory, were used.
M-234p:
Is a type B (16) moderately differentiated mammary adenocarcinoma that shows a mixed pattern and develops lung metastasis. It spontaneously arose in a BALB/c female mouse, and it is maintained in vivo by serial subcutaneous passages in syngeneic mice, with 100% of incidence.
M-406:
Is a type B semi-differentiated mammary adenocarcinoma which appeared spontaneously in an inbred CBi female mouse. It is maintained in vivo by serial intraperitoneal passages in syngeneic mice, with 100% of incidence. Bouin's solution to determine the number and size of metastatic foci. With both data the total metastatic burden/mouse was calculated.
Treatment comparison.
As we had previously demonstrated that the therapeutic efficacy of the combined treatment groups was significantly higher than that achieved with each individual drug, the data herein analyzed were those belonging to the groups of animals that received MCT with both drugs. For the efficacy comparison we calculated the percentages of reduction with respect to each control group of both, tumor and lung metastatic volumes of each group of combined treatment. In the same way, the percentages of survival increase with respect to controls were also determined and statistically compared.
Statistical analysis
Kruskal-Wallis and Dunn's Multiple Comparison Test were used to examine the differences between groups with GraphPad Prism® version 3.0 (GraphPad Software, San Diego, CA). Differences were considered statistically significant at P < 0.05.
RESULTS
As previously informed, both treatments significantly inhibited tumor growth (5, 14) . The between tumor-models (Kruskal-Wallis non-parametric ANOVA) ( Table 1 ).
Mice that received MCT with Cy+Cel or Cy+Dox, showed a significantly higher survival than the corresponding control mice in both tumor models. When treatments were compared to each other, and interesting effect was observed, while in the (Table 3) The surrogate markers of morbidity/toxicity monitored, namely the motor activity, fur quality, food intake, response to stimuli and breathing, plus the evolution of body weight and total leucocytes count showed no differences with respect to their respective controls, along the experiments, independently of the tumor-models or treatments (Data not shown).
DISCUSSION
The combination of two or more existing chemotherapy agents in order to achieve therapeutic synergism is an interesting goal in most of the metronomic schedules assayed.
A Some of them were developed in tumor-models of mammary adenocarcinomas (18, (21) (22) (23) 26) . The therapeutic results achieved with the different drugs combinations were variable.
Also, those therapeutic schedules were accompanied by the presence or absence of toxic effects. Hence, it is somewhat difficult to identify which is, for a determined type of tumor, the best metronomic drug combination in terms of efficacy and derived toxicity, two
properties that in turn, will determine the extension and the quality of life of the tumor bearers.
Following this line of thought we decided to compare the antitumor and the antimetastatic efficacy of the two drug combinations tested in our lab to treat two murine mammary adenocarcinomas.
The antitumor efficacy and the increase in survival did not show statistical differences, either among treatments or tumor-models. On the other hand, the combination of Cy+Cel was superior than Cy+Dox related to antimetastatic power, suggesting its potential use at the adjuvant setting.
In matter of toxicity, both treatments showed low to null toxic effects. No weight losses were detected throughout the experiment in any of the groups of both tumor models. Also, no alterations were found in the markers of morbidity/toxicity monitored (5, 14) .
Therefore, the quality of life in both combinations would be similar. Nevertheless, if we take into consideration that the administration of Cy+Cel is exclusively oral, while the Cy+Dox schedule has the drawback of the Dox intraperitoneal injection, the scale tilts into the Cy+Cel direction. The availability of such data would enable to compare different schedules and combinations of MCT for mammary tumors for their translation to the clinic.
In the meantime, in the clinical field, metronomic Cy+Cel schedule for treating advanced breast cancer patients is being tested, showing a good response and low to null toxicity (26).
In conclusion, although both combined metronomic treatments were fairly similar respect to the absence of toxicity and to the inhibition of tumor growth, leading to an increased survival, the election of the Cy+Cel combination as the better one, was based in its antimetastatic power and also because of the advantage that represents its oral administration. The last one is not a minor advantage, since the development of these oral chemotherapies allows an effective treatment with an easy drug administration, with less significant adverse effects, providing better outpatient management without the emotional burden that intravenous chemotherapy represents. 
